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Background: In heart failure (HF) patients, increased arginine vasopressin (AVP) activity is associated with poor prognosis, making AVP an 
attractive target for therapy. However, AVP is difficult to measure due to its instability and rapid clearance. Copeptin, the C-terminal segment of pre-
pro-vasopression, is a stable and sensitive biomarker for AVP release.
Methods: The BACH trial was a prospective, 15-center diagnostic and prognostic study of 1641 patients with acute dyspnea. A secondary endpoint 
of the study was to evaluate the prognostic utility of copeptin in patients diagnosed with acute HF. Patients were followed for up to 90 days after 
initial evaluation.
Results: 556 patients had a final diagnosis of HF. Patient with copeptin levels in the highest quartile had increased 90 day mortality (p<.001). 
(Figure 1) Patients with copeptin levels above median (1.43 pmol/L) and sodium levels below median (139 mEq/L) also had increased 90 day 
mortality (p=.004). In high and low sodium groups based on median split, mortality is increased in the highest copeptin quartile in both groups. Of 
note, there is poor correlation between copeptin and sodium (R=.047).
Conclusions: This study has shown significantly increased 90 day mortality in patients with elevated copeptin, especially in the highest copeptin 
quartile. These findings provide a crucial piece of prognostic information in patients with acute HF, making it feasible for future guided AVP 
antagonist therapy in HF patients with elevated copeptin levels.
